111 Capital Sells 9,679 Shares of Gilead Sciences, Inc. $GILD

111 Capital reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,908 shares of the biopharmaceutical company’s stock after selling 9,679 shares during the period. 111 Capital’s holdings in Gilead Sciences were worth $2,540,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. QRG Capital Management Inc. raised its position in Gilead Sciences by 6.9% in the 2nd quarter. QRG Capital Management Inc. now owns 299,587 shares of the biopharmaceutical company’s stock valued at $33,215,000 after buying an additional 19,277 shares during the last quarter. Jackson Wealth Management LLC raised its position in Gilead Sciences by 15.4% in the 2nd quarter. Jackson Wealth Management LLC now owns 4,747 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 633 shares during the last quarter. Stock Yards Bank & Trust Co. raised its position in Gilead Sciences by 1,069.8% in the 2nd quarter. Stock Yards Bank & Trust Co. now owns 25,220 shares of the biopharmaceutical company’s stock valued at $2,796,000 after buying an additional 23,064 shares during the last quarter. Ascent Group LLC raised its position in Gilead Sciences by 52.7% in the 2nd quarter. Ascent Group LLC now owns 49,324 shares of the biopharmaceutical company’s stock valued at $5,469,000 after buying an additional 17,016 shares during the last quarter. Finally, Ameritas Advisory Services LLC raised its position in Gilead Sciences by 12.6% in the 2nd quarter. Ameritas Advisory Services LLC now owns 5,492 shares of the biopharmaceutical company’s stock valued at $609,000 after buying an additional 616 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Up 1.9%

Shares of GILD opened at $112.69 on Friday. The business has a 50-day moving average of $114.34 and a 200 day moving average of $109.92. Gilead Sciences, Inc. has a fifty-two week low of $83.98 and a fifty-two week high of $121.83. The firm has a market cap of $139.83 billion, a P/E ratio of 22.45, a price-to-earnings-growth ratio of 0.75 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm posted $2.01 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GILD. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Rothschild & Co Redburn increased their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Finally, Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.